Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(15):1045; doi:10.1093/jnci/djn282
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Competing Risks Analysis of Epirubicin Cardiotoxicity

Present recommendations for maximum cumulative dosage of epirubicin during chemotherapy have been calculated based on this drug's risk of cardiotoxicity in the general population. However, a better estimate of optimum dosage can be obtained for defined patient subgroups when other factors that put them at risk of death from congestive heart failure and the competing factors that put them at risk of death from other causes, including cancer, are taken into account. Ryberg et al. (p. 1058) used data from a Danish population of patients with metastatic breast cancer to define patient characteristics that are associated . . . [Full Text of this Article]

Smoking Among Adult Survivors of Childhood Cancer in Britain

Screening Mammography: Vermont versus Norway

Effect of Lapatinib on Breast Cancer Metastasis to Brain

mtDNA Heritability and Renal Cell Carcinoma

Inhibition of tumor growth using Salmonella expressing FasL


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?